Clinical trials: Attention Deficit Disorder with Hyperactivity (ADHD)
- Condition Attention Deficit Disorder with Hyperactivity (ADHD)
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder (ADHD)
LearningRx Cognitive Training for ADHD
The purpose of this investigation is to conduct a series of case studies on the impact of LearningRx cognitive training on cognitive skills, brain structure, and daily functioning for participants with ADHD.
- Trial name
- NCT02917109
- Testing
- LearningRx cognitive training
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Gibson Institute of Cognitive Research
ADHD Specifically With Executive Function Impairment
Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo on executive function (self-regulation) behaviors in adults with ADHD who report clinically significant impairment of executive function…
- Trial name
- NCT01101022
- Testing
- SPD489
- Where
- 39 sites in United States
- Volunteers
- 161 people
- Sponsor
- Shire
ADHD
Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To assess the efficacy and safety of efficacy of MTS compared to placebo
- Trial name
- NCT00499863
- Testing
- methylphenidate transdermal system
- Where
- 32 sites in United States
- Volunteers
- 217 people
- Sponsor
- Noven Therapeutics
Attention-Deficit/Hyperactivity Disorder
Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks
- Trial name
- NCT00191035
- Testing
- Atomoxetine
- Where
- 21 sites in United States
- Volunteers
- 520 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of Impulsive Aggression (IA) in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with…
- Trial name
- NCT02618408
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 28 sites in United States
- Volunteers
- 333 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder
A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.
- Trial name
- NCT00554385
- Testing
- ABT-089
- Where
- 23 sites in United States
- Volunteers
- 283 people
- Sponsor
- Abbott
Attention-Deficit/Hyperactivity Disorder
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.
- Trial name
- NCT00391729
- Testing
- ABT-089
- Where
- 23 sites in United States
- Volunteers
- 221 people
- Sponsor
- Abbott
Attention Deficit Hyperactivity Disorder
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years
The objective of this study was to evaluate the plasma amphetamine concentration/time profile of amphetamine extended release oral suspension in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following…
- Trial name
- NCT03610464
- Testing
- Amphetamine Extended Release Suspension [Dyanavel]
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type
Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, impulsivity, and impaired executive functioning.
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type, ADHD
- Trial name
- NCT07173439
- Testing
- Model Name: EMT-SR01;red
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- EMOTIV
ADHD
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
To evaluate the efficacy of AMPH ER TAB compared to placebo in adult patients with ADHD aged 18 to 60 years.
- Trial name
- NCT03834766
- Testing
- AMPH ER Tab 5, 10, 15 and 20 mg
- Where
- 3 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder
A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.
A 6-week double-blind study to evaluate the safety and efficacy of Quillichew extended release chewable tablets in 4-5 year old children with attention deficit hyperactivity disorder.
- Trial name
- NCT03580005
- Testing
- methylphenidate HCl ERCT
- Sponsor
- Pfizer
Healthy, CVA
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
DELPhI software developed for the analysis of EEG recordings in response to magnetic stimulation in relation to clinical data.
- Conditions
- Healthy, CVA, Hemorrhage, TBI (Traumatic Brain Injury)
- Trial name
- NCT04095377
- Testing
- No intervention, this is a retrospective study.
- Where
- Israel
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Attention Deficit Hyperactivity Disorder
Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)
Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period.
- Trial name
- NCT01472991
- Testing
- TC-5619-238 5mg, TC-5619-238 25mg
- Where
- 14 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD.
- Trial name
- NCT02402166
- Testing
- SPD489
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Therapeutic Gaming for the Treatment of Attention Deficit Hyperactivity Disorder
Children with ADHD play a videogame to test symptom control
- Trial name
- THERAGAME (NCT05067322)
- Testing
- Minecraft
- Volunteers
- 2 people
- Sponsor
- Spherix Incorporated
Attention-Deficit/Hyperactivity Disorder
A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention-Deficit/Hyperactivity Disorder or ADHD.
- Trial name
- NCT00528697
- Testing
- ABT-089, atomoxetine
- Where
- 20 sites in United States
- Volunteers
- 278 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Attention Deficit Hyperactivity Disorder
Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD
This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with ADHD.
- Trial name
- NCT00556296
- Testing
- NRP104
- Volunteers
- 297 people
- Sponsor
- New River Pharmaceuticals
ADHD
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.
- Trial name
- NCT00367835
- Testing
- SPD503 (Guanfacine hydrochloride)
- Where
- 34 sites in United States
- Volunteers
- 217 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)
The purpose of this study is to evaluate the effects of videogame-like digital therapy on attentional functioning and symptoms in adolescents ages 13-17 diagnosed with ADHD
- Trial name
- NCT04897074
- Testing
- AKL-T01
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder
Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder
Open-label trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 years with Attention- Deficit/Hyperactivity Disorder
- Trial name
- NCT00191880
- Testing
- atomoxetine
- Where
- 8 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company